Cancer Vaccines
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Published in Vaccine Weekly, November 21st, 2007
GARDASIL(R) (Human Papillomavirus Quadrivalent) (Types 6, 11, 16, 18) Vaccine, Recombinant) prevented 91 percent of cases of persistent infection, low-grade cervical abnormalities, and pre-cancers, and external genital lesions caused by HPV types 6, 11, 16 and 18 compared with placebo in women aged 24 through 45, according to new data presented today at the 24th International Papillomavirus Conference (IPC) in Beijing, China.
The primary results evaluated women who were free of infection from at least one vaccine HPV type when they began the study, and who remained free of infection with the relevant HPV type(s) until they completed the three-dose vaccination regimen....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-11-21)
More Articles from Vaccine Weekly
- DNA Vaccines
Researchers from University of Duisburg-Essen report recent findings in DNA vaccines - Vaccine Efficacy
Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles - Angiotensins
Research on angiotensins detailed by scientists at Peking Union Medical College - Anthrax Therapy
Studies conducted at Naval Medical Research Center on anthrax therapy recently published - Cytomegalovirus Vaccines
AlphaVax, Inc. publishes research in cytomegalovirus vaccines - DNA Vaccines
Studies from N. Ternette and colleagues provide new data on DNA vaccines - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
